Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The different mechanisms of action between Antithymocyte globulin and cyclosporine can
improve the effectivity when both are used in combination in patients with myelodysplastic
syndrome.